Inotuzumab ozogamicin - Pfizer

Drug Profile

Inotuzumab ozogamicin - Pfizer

Alternative Names: Besponsa; CMC-544; PF-5208773; WAY-207294

Latest Information Update: 11 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Celltech Group
  • Developer Cancer Research UK; Children's Oncology Group; M. D. Anderson Cancer Center; National Cancer Institute (USA); Pfizer; SWOG; University College London; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Cytostatic antibiotics; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action CD22 antigen inhibitors; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute lymphoblastic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Acute lymphoblastic leukaemia
  • Phase I/II Chronic myeloid leukaemia
  • No development reported Burkitt's lymphoma
  • Discontinued Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 30 Nov 2017 Phase-II clinical trials in Acute lymphoblastic leukaemia (In adolescents, Second-line therapy or greater, In children) in USA (IV) (NCT03094611)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Burkitt's-lymphoma(Combination therapy, Second-line therapy or greater) in USA (IV, Infusion)
  • 17 Aug 2017 The approved US label for Inotuzumab ozogamicin carries a black box warning for hepatotoxicity, including hepatic veno-occlusive disease and increased risk of post-HSCT non-relapse mortality
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top